Literature DB >> 10542436

Nicotinic receptors in the brain: correlating physiology with function.

S Jones1, S Sudweeks, J L Yakel.   

Abstract

Nicotinic ACh receptors (nAChRs) have been implicated in a variety of brain functions, including neuronal development, learning and memory formation, and reward. Although there are substantial data indicating that nAChR subunits are found in many brain regions, the precise cellular roles of these subunits in neuronal functions have remained elusive. Until recently, nAChRs were thought primarily to serve a modulatory role in the brain by regulating neurotransmitter release from nerve terminals. However, new evidence has revealed that nAChRs also function in a postsynaptic role by mediating fast ACh-mediated synaptic transmission in the hippocampus and in the sensory cortex, and are found at somatodendritic as well as nerve terminal sites in the reward system. It is possible that presynaptic and postsynaptic nAChRs mediate changes in the efficacy of synaptic transmission in these brain regions. These changes could underlie the proposed functions of nAChRs in cognitive functions of the hippocampus and cerebral cortex, in neuronal development in the sensory cortex, and in reward.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542436     DOI: 10.1016/s0166-2236(99)01471-x

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  118 in total

Review 1.  Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses.

Authors:  Kyung-Hye Huh; Christian Fuhrer
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  A critical period for nicotine-induced disruption of synaptic development in rat auditory cortex.

Authors:  V B Aramakis; C Y Hsieh; F M Leslie; R Metherate
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Nicotinic alpha 7 receptor clusters on hippocampal GABAergic neurons: regulation by synaptic activity and neurotrophins.

Authors:  Hideki Kawai; Wagner Zago; Darwin K Berg
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 4.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Chronic nicotine treatment differentially modifies acute nicotine and alcohol actions on GABA(A) and glutamate receptors in hippocampal brain slices.

Authors:  William R Proctor; Peter Dobelis; Anna T Moritz; Peter H Wu
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

6.  Fast synaptic transmission in the goldfish CNS mediated by multiple nicotinic receptors.

Authors:  Charlotte L Grove; Theresa M Szabo; J Michael McIntosh; Samantha C Do; Robert F Waldeck; Donald S Faber
Journal:  J Physiol       Date:  2010-11-29       Impact factor: 5.182

7.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

Review 8.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

9.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

10.  PMCA2 via PSD-95 controls calcium signaling by α7-containing nicotinic acetylcholine receptors on aspiny interneurons.

Authors:  David Gómez-Varela; Manuela Schmidt; Jeff Schoellerman; Eric C Peters; Darwin K Berg
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.